BioCentury | Jul 9, 2020
Finance

July 8 Quick Takes: CapitalBio raises $113M, plans Shanghai IPO; plus Aidea, CF PharmTech, Denovo, Nucleai and Vaxdyn

...Hengxu, GP M&A Fund and Watson Investment, as well as existing investors Passion Capital and Yuanming Capital...
BioCentury | Oct 16, 2019
Financial News

China-heavy syndicate backs $80M series B for antiviral play Ansun

...Ansun BioPharma Inc.’s $80 million series B round with participation by fellow existing Chinese investors Yuanming Capital...
BioCentury | Apr 25, 2019
Finance

The academic founders' conundrum

...2018 JW Therapeutics (Shanghai) Co. Ltd. Shanghai, China $90.0 Temasek , Sequoia Capital China , YuanMing Capital...
BioCentury | Jul 13, 2018
Company News

Adlai Nortye gets rights to buparlisib from Novartis

...Last month, Adlai Nortye raised over $50 million in a series B round led by YuanMing Capital...
BioCentury | Jul 10, 2018
Company News

Adlai Nortye gets rights to Novartis' buparlisib

...Last month, Adlai Nortye raised over $50 million in a series B round led by YuanMing Capital...
BioCentury | Jun 29, 2018
Financial News

Adlai Nortye raises $50M series B

...Co. Ltd. (Hangzhou, China) raised over $50 million in a series B round led by YuanMing Capital...
BioCentury | Jun 26, 2018
Financial News

Adlai Nortye raises $50M in series B

...Co. Ltd. (Hangzhou, China) raised over $50 million in a series B round led by YuanMing Capital...
...is in Phase Ib testing. Mary Romeo E7046 Reolysin, pelareorep Adlai Nortye Biopharma Co. Ltd. Eisai Co. Ltd. Matrix Partners Oncolytics Biotech Inc. YuanMing Capital Prostaglandin...
BioCentury | May 18, 2018
Finance

Ansun’s China ambitions

...Lilly Asia Ventures led the round, with participation from fellow new Chinese investors Lyfe Capital, Yuanming Capital...
BioCentury | May 18, 2018
Financial News

Ansun raises $85M series A, plans Phase III for anti-viral

...round led by Sinopharm Healthcare Fund and Lilly Asia Ventures. New investors included Lyfe Capital, Yuanming Capital...
BioCentury | May 14, 2018
Financial News

Ansun raises $85M series A, plans Phase III for anti-viral

...round led by Sinopharm Healthcare Fund and Lilly Asia Ventures. New investors included Lyfe Capital, Yuanming Capital...
Items per page:
1 - 10 of 21
BioCentury | Jul 9, 2020
Finance

July 8 Quick Takes: CapitalBio raises $113M, plans Shanghai IPO; plus Aidea, CF PharmTech, Denovo, Nucleai and Vaxdyn

...Hengxu, GP M&A Fund and Watson Investment, as well as existing investors Passion Capital and Yuanming Capital...
BioCentury | Oct 16, 2019
Financial News

China-heavy syndicate backs $80M series B for antiviral play Ansun

...Ansun BioPharma Inc.’s $80 million series B round with participation by fellow existing Chinese investors Yuanming Capital...
BioCentury | Apr 25, 2019
Finance

The academic founders' conundrum

...2018 JW Therapeutics (Shanghai) Co. Ltd. Shanghai, China $90.0 Temasek , Sequoia Capital China , YuanMing Capital...
BioCentury | Jul 13, 2018
Company News

Adlai Nortye gets rights to buparlisib from Novartis

...Last month, Adlai Nortye raised over $50 million in a series B round led by YuanMing Capital...
BioCentury | Jul 10, 2018
Company News

Adlai Nortye gets rights to Novartis' buparlisib

...Last month, Adlai Nortye raised over $50 million in a series B round led by YuanMing Capital...
BioCentury | Jun 29, 2018
Financial News

Adlai Nortye raises $50M series B

...Co. Ltd. (Hangzhou, China) raised over $50 million in a series B round led by YuanMing Capital...
BioCentury | Jun 26, 2018
Financial News

Adlai Nortye raises $50M in series B

...Co. Ltd. (Hangzhou, China) raised over $50 million in a series B round led by YuanMing Capital...
...is in Phase Ib testing. Mary Romeo E7046 Reolysin, pelareorep Adlai Nortye Biopharma Co. Ltd. Eisai Co. Ltd. Matrix Partners Oncolytics Biotech Inc. YuanMing Capital Prostaglandin...
BioCentury | May 18, 2018
Finance

Ansun’s China ambitions

...Lilly Asia Ventures led the round, with participation from fellow new Chinese investors Lyfe Capital, Yuanming Capital...
BioCentury | May 18, 2018
Financial News

Ansun raises $85M series A, plans Phase III for anti-viral

...round led by Sinopharm Healthcare Fund and Lilly Asia Ventures. New investors included Lyfe Capital, Yuanming Capital...
BioCentury | May 14, 2018
Financial News

Ansun raises $85M series A, plans Phase III for anti-viral

...round led by Sinopharm Healthcare Fund and Lilly Asia Ventures. New investors included Lyfe Capital, Yuanming Capital...
Items per page:
1 - 10 of 21